A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer

Inclusion Criteria

• •Participants must have histologically confirmed operable triple negative breast cancer
• •* ER (estrogen receptors) and PR (progesterone receptors) expression must be \< 2%
• •* HER2 must negative as shown be either 0 or 1+ by immunohistochemistry (if 2+, in situ hybridization method used to define HER2) OR by a HER2: 17 centromere signal of \<2.0 using a standard in situ hybridization method.
• •No prior therapy for current breast cancer
• •Operable breast cancer. Participants who are planned to undergo neo-adjuvant chemotherapy are eligible as long as they consent to an additional breast biopsy following the dietary intervention immediately prior to starting chemotherapy
• •ECOG (Eastern Cooperative Oncology Group) performance status ≤1
• •Ability to understand and the willingness to sign a written informed consent document
• •Serum creatinine \<ULN (upper limit of normal)
• •Non-pregnant. Women of childbearing potential must have a negative pregnancy test to participate in this study
• •Women of childbearing potential must agree to use effective contraceptives (as discussed with their physician) while participating in this study